CABA
Cabaletta BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If 1H26 data remain supportive across SLE, SSc and MG, and automated manufacturing plus no-preconditioning approaches look viable, Cabaletta could move from a single-program story toward a broader autoimmune platform with materially higher strategic value.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +5.0.
What can break
Cash runway only into Q4 2026 raises financing risk if timelines slip or data do not strengthen partnering leverage.
Momentum
89
Value
41
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.60 · Bull $6.00 · Bear $1.60
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $13.57
Why
Momentum89 · Δ7d +5.0
Value41 · Δ7d +0.1
Sentiment47 · Δ7d +2.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
34% active weight
Current posture
7d trendFlat
Δ7d
+5.0
Δ21d
+2.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
47
33% active weight
Current posture
7d trendImproving
Δ7d
+2.7
Δ21d
+11.5
Why this grade
Composite grade B. Momentum 89.2 / Value 41.1 / Sentiment 46.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$598.41M
Beta
3.26
Shares Out
96.27M
P/E (TTM) · Derived
-2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.45
Rev YoY
-
EPS YoY
+29.1%
Gross Margin
-
Op Margin
-
Net Debt
-$154.73M
Current Ratio
3.60
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology